A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE, STUDY OF SUROVATAMIG AS CONSOLIDATION THERAPY VERSUS OBSERVATION AFTER FIRST-LINE INDUCTION THERAPY IN PARTICIPANTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WITH UNMUTATED IGHV (SOUNDTRACK-C1)

Registry ID

D7409C00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA AB

Start date

2026-05-08

Last update

2025-12-04

Conditions

• CHRONIC LYMPHOCYTIC LEUKEMIA
• SMALL LYMPHOCYTIC LYMPHOMA

Related clinical trials

• AN OPEN-LABEL, PHASE 1/2 STUDY OF JCAR017 IN SUBJECTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
• A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF 3 DOSES OF PIRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WHO PREVIOUSLY RECEIVED TREATMENT WITH A COVALENT BRUTON TYROSINE KINASE INHIBITOR
• A PHASE 3, RANDOMIZED STUDY TO COMPARE NEMTABRUTINIB VERSUS COMPARATOR (INVESTIGATOR'S CHOICE OF IBRUTINIB OR ACALABRUTINIB) IN PARTICIPANTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BELLWAVE-011)
• A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF SONROTOCLAX (BGB-11417) PLUS ZANUBRUTINIB (BGB-3111) COMPARED WITH VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
• MULTICOHORT STUDY TO CUSTOMIZE IBRUTINIB TREATMENT REGIMENS FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
• PHASE I/IB STUDY OF TBI-2001 FOR PATIENTS WITH RELAPSED OR REFRACTORY CD19+ B-CELL LYMPHOMA, CHRONIC LYMPHOCYTIC LYMPHOMA (CLL), SMALL LYMPHOCYTIC LYMPHOMA (SLL)

View on source registry